Two multicenter studies find group A plasma in trauma shows no increased mortality for incompatible patients.
Only about 4% of the world is group AB, while the one-to-one-to-one ratio has pushed plasma use up. Blood centers keep AB donors giving as often as possible, but when trauma centers ask for a 20% AB supply, the demand outruns the population genetics.
Tate Stevens says that somewhere around 85% of the time it probably does not matter much, because group A plasma is compatible with group O and group A patients, who are the majority. That leaves the remaining 15%, group B and AB recipients, and how often that is a problem.
No observable difference was seen between the two populations in overall mortality, mortality in the initial 24 hours, or hospital length of stay. The incompatible group did have more penetrating injury, yet group B and AB recipients were not dying more often than their age, injury severity and mechanism predicted.
Seventeen centers agreed to participate, sixteen in the United States and one in the UK; other centers using group A plasma declined. The power calculation called for roughly 354 patients in the incompatible group, and the identical group held 809 group A patients, since group A is far more common.
Group O people clot differently, typically with lower factor VIII and von Willebrand factor. For them group A plasma is neither identical nor incompatible: nothing on their red cells risks hemolysis, but soluble A substance in the plasma might confound the result. With plenty of group A patients for comparison, they were excluded.
Very few transfusion reactions were reported at all, and none in the incompatible group; the larger identical group had more. The only hemolytic reaction detected was in the identical group, and it was due to a red cell antibody against the Duffy A antigen not known at admission.
Basically no difference: no difference in rates of any of the morbidities drawn from the trauma registry, in length of stay, or in transfusion reactions, with two trolleys in the compatible group and none in the incompatible group. The incompatible group did receive more plasma, which the authors could not explain.
Of the 1,500 and some adults on whom massive transfusion protocol was activated, 120 were group B or AB and received incompatible type A plasma, about 8%. That is lower than expected because a couple of centers acted as controls using group AB plasma, contributing only to the compatible group.
Nancy Dunbar's survey of level one trauma centers, from data in 2015, found that 63% used group A plasma in the initial phase of resuscitation for patients of unknown ABO group. The majority were maintaining thawed A plasma inventories before either outcome paper was published.
Joe Chaffin treats group A plasma as a bridge product, not a forever product: it carries the patient until freshly thawed, ideally ABO identical plasma is ready, so getting a sample for an ABO type is vital. Dartmouth limits patients to four units, while 62% of surveyed centers set no limit.
“Our results were that there was basically no difference.”
“All we've been able to show, which is something, is that it doesn't appear to increase the risk of mortality.”
“I tell them to talk to Nancy.”
“036: Group A Plasma in Trauma with Nancy Dunbar & Tait Stevens.” https://www.youtube.com/watch?v=ibVYC7dW3iY. Transcript summary by WhipScribe, https://whipscribe.com/transcript-pages/036-group-a-plasma-in-trauma-with-nancy-dunbar-tait-stevens.html.